PERIO-02: Phase 1b pressure enabled regional immuno-oncology trial of nelitolimod (SD-101), a class C TLR9 agonist, delivered via hepatic artery infusion +/- checkpoint inhibition in intrahepatic cholangiocarcinoma and hepatocellular carcinoma.
Year: 2024
Type: conference-abstract
Source: Journal of Clinical Oncology
Authors: Sunyoung S. Lee, Khaldoun Almhanna, Rahul Sheth, Shubham Pant, Joshua Kuban, Aaron Wilhelm Palmer Maxwell, Brian Justin Witt, Jason LaPorte, Ann-Marie Hulstine, Bryan Cox, Richard D. Carvajal, Ruth Aroon White, Joshua Weintraub, Lindsey Davis, James Hart, Robert D. Knight, Steven C. Katz, Milind M. Javle
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W4399662781